Triple-negative breast cancer

Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023

Retrieved on:

Tuesday, October 24, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA.

Key Points:

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA.
The poster presentations will highlight 9 drug assets and 7 gene-edited humanized mouse models:
DM005, an EGFR х MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models
BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy in vivo
A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts
To explore licensing and collaboration opportunities for drug assets, fully human antibody/TCR discovery platforms, off-the-shelf animal/cell models, or preclinical pharmacology services, please visit booth 223.

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Retrieved on:

Tuesday, October 17, 2023

Cancer, Pharmacokinetics, NSCLC, Trial of the century, Triple-negative breast cancer, Lung cancer, Safety, Ovarian cancer, Immunotherapy, Tumor-associated macrophage, Clinical trial, Colorectal cancer, Head, TNBC, Renal cell carcinoma, Patient, Tams, Vaccine, Pharmaceutical industry

The study will evaluate BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer (TNBC), colorectal cancer, clear cell renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), or ovarian cancer.

Key Points:

The study will evaluate BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer (TNBC), colorectal cancer, clear cell renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), or ovarian cancer.
“We are excited to have dosed the first patient in this first-in-human clinical trial, which will evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BDC-3042 in a diverse set of advanced cancers,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.
“BDC-3042 is a monoclonal antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells and is the first-in-class Dectin-2 agonist.
“In preclinical studies, BDC-3042 has shown the ability to repolarize TAMs from a tumor-supportive to a tumor-destructive phenotype.”

Lilly Announces Details of Presentations at ESMO Congress 2023

Retrieved on:

Friday, October 6, 2023

In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Key Points:

In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.
A separate poster presentation will provide data on the impact of dose reductions on efficacy for patients treated in monarchE.
In two late-breaking oral presentations that will be featured as part of the Presidential Symposium 1 on Saturday, October 21, Lilly will share interim analysis results from the Phase 3 LIBRETTO-431 and LIBRETTO-531 clinical studies.
In a mini oral presentation, Lilly will share clinical data on imlunestrant as a single agent and in combination therapy.

Annexin announces success in the company's cancer initiative

Retrieved on:

Friday, September 29, 2023

Triple-negative breast cancer, Cancer, PS, Protein, Annexin Pharmaceuticals, Cell, Research, Patient, CMO, CSO, Breast cancer, Vaccine, Pharmaceutical industry, Fine chemical

STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.

Key Points:

STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.
In cell systems outside the body, this ANXV conjugate has been shown to kill a type of cancer cell taken from a person with triple-negative breast cancer, a very difficult-to-treat form of breast cancer.
Annexin has chosen to drive development towards new cancer treatments based on the fact that many different cancer cells expose the substance phosphatidylserine (PS), ANXV's target molecule, on their surface.
The principle of linking chemotherapy drugs to proteins that target cancer cells is well known and used in many approved drugs.

Annexin announces success in the company's cancer initiative

Retrieved on:

Friday, September 29, 2023

Triple-negative breast cancer, Cancer, PS, Protein, Annexin Pharmaceuticals, Cell, Research, Patient, CMO, CSO, Breast cancer, Vaccine, Pharmaceutical industry, Fine chemical

STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.

Key Points:

STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells.
In cell systems outside the body, this ANXV conjugate has been shown to kill a type of cancer cell taken from a person with triple-negative breast cancer, a very difficult-to-treat form of breast cancer.
Annexin has chosen to drive development towards new cancer treatments based on the fact that many different cancer cells expose the substance phosphatidylserine (PS), ANXV's target molecule, on their surface.
The principle of linking chemotherapy drugs to proteins that target cancer cells is well known and used in many approved drugs.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on:

Wednesday, September 27, 2023

Triple-negative breast cancer, Society, Euronext Growth, San Diego Convention Center, SITC, Immunotherapy, PDT, EDT, CAR, Journal, JITC, Poster, MUC1, Vaccine, Cellectis

Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.

Key Points:

Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.
Title: TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer.
Date/Time: Poster will be on display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
Full text of the abstract will be made public on October 31, 2023 at 9:00 a.m. EDT on the SITC website and in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.

Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting

Retrieved on:

Wednesday, September 27, 2023

SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC 2023 (Society for Immunotherapy of Cancer 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California.

Key Points:

SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC 2023 (Society for Immunotherapy of Cancer 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California.
The highlighted abstracts for SITC 2023 include:
By analyzing the tumor microenvironment (TME) with Lunit SCOPE IO, one study explores the treatment response of non-small cell lung cancer (NSCLC) patients with EGFR mutations to immune checkpoint inhibitors (ICI) after acquiring resistance to EGFR tyrosine kinase inhibitors (TKI).
Visit Lunit's booth at SITC 2023 at Booth 227 to learn more about these pioneering studies.
To schedule a meeting with the Lunit team, please reach out to [email protected] .

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on:

Wednesday, September 27, 2023

Triple-negative breast cancer, Abstract, TNBC, Society, TIL, SITC, Immunotherapy, Lyell, NSCLC, Lung cancer, CAR, Patient, SAN, EPI, Pharmaceutical industry, Medical imaging, Vaccine

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in San Diego, Nov. 1-5, 2023.

Key Points:

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in San Diego, Nov. 1-5, 2023.
“Our presentations at SITC highlight the progress we are making on several fronts to advance new product candidates and technologies designed to generate potent and durable cell therapies for patients with solid tumors,” stated Dr. Gary Lee, chief scientific officer at Lyell.
Two additional presentations highlight the design of Lyell’s ongoing Phase 1 clinical trials in progress: LYL797, a ROR1-targeted CAR T-cell therapy being evaluated in a Phase 1 trial in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer, and LYL845, a tumor infiltrating lymphocyte (TIL) therapy being evaluated in a Phase 1 trial in advanced solid tumors.
Details on the six poster presentations are below:
Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023

Retrieved on:

Wednesday, September 27, 2023

Onchilles Pharma , a private biotech company developing new pan-cancer therapeutics that leverage a novel mechanism of action, announced today the presentation of preclinical data for the N17350 program at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1-5, 2023.

Key Points:

Onchilles Pharma , a private biotech company developing new pan-cancer therapeutics that leverage a novel mechanism of action, announced today the presentation of preclinical data for the N17350 program at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1-5, 2023.
N17350, is a first-in-class biologic therapeutic inspired by the immunobiology of neutrophils, with the potential to be effective against a wide range of cancer types.
The company is targeting to start first-in-human clinical trials in skin cancers, head and neck cancer, and triple-negative breast cancer in 2024.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on:

Tuesday, September 19, 2023

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points:

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.